-->

OPKO Health jumps on Merck licensing deal

Post a Comment
The Stock you NEED in your portfolio

NASDAQ recently said this could become a "millionaire-making stock." Discover the details of this early-stage tech stock that has all the right ingredients to be one of the MAJOR tech millionaire-makers of the decade!

Click here to get the #1 tech stock you need. 
[ad]
Reagan's "Secret Currency" Uncovered

This is the Ronald Reagan story you've likely never been told. Over 40 years ago, Reagan took swift action against an ongoing crisis and unlocked one of the most profitable investments of the decade. It has nothing to do with gold or any stock. But right now, in 2023, Reagan's secret investment is making a massive comeback. Leading to potential future growth as high as 24,900% in one brand new asset class.

Click here for the full story.
 
[ad]
Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

Analyze Any Stock Free
 [ad]

OPKO Health Inc (NASDAQ:OPK) shares surged Wednesday on the back of news that its ModeX Therapeutics company has entered into an exclusive global license and collaboration agreement with Merck & Company Inc (NYSE:MRK) for the development of MDX-2201, ModeX's preclinical nanoparticle vaccine candidate targeting EBV.


If there was one piece of advice the boss of hedge fund Citadel LLC would give to the Federal Reserve, it would be to stop talking so much.






DISCLAIMER: Stocks and options trading have large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stocks and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell stocks or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed in this report. The past performance of any trading system or methodology is not necessarily indicative of future results. All trades, patterns, charts, systems, etc., discussed in this report are for illustrative purposes only and not to be construed as specific advisory recommendations. Information contained in this correspondence is intended for informational purposes only and was obtained from sources believed to be reliable. Information is in no way guaranteed. No guarantee of any kind is implied or possible where projections of future conditions are attempted.








2563 cherry hill ln, Hermitage, PA 16148, United States
You may unsubscribe or change your contact details at any time.

Related Posts

There is no other posts in this category.

Post a Comment

Subscribe Our Newsletter